Latest from Yale Cancer Center

The role of immunotherapy in metastatic renal cell carcinoma has grown tremendously with dual immune checkpoint inhibition and combinations of anti–PD-1/VEGF inhibitors.

Francine Foss, MD, discusses the challenges faced in cutaneous T-cell lymphoma.

Barbara Burtness, MD, discusses the effectiveness of immunotherapy in patients with platinum-refractory head and neck cancers. 

Daniel P. Petrylak, MD, discusses the current treatment landscape of metastatic urothelial carcinoma and exciting strategies in the pipeline.

Daniel P. Petrylak, MD, professor of medicine and urology, co-leader of Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care^® in Genitourinary Cancers, shares exciting prostate cancer and bladder cancer data presented at the 2020 Genitourinary Cancers Symposium.

Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the importance of taking proactive measures to prevent the spread of the novel 2019 coronavirus.

Daniel P. Petrylak, MD, discusses available treatment options in metastatic bladder cancer.

In metastatic urothelial cancer, the portfolio of immunologic therapies is robust, but the treatment paradigm for these agents requires refinement.